Exhibit 99.1

FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

Cardiome Pharma Corp.

6190 Agronomy Rd, 6^th Floor

Vancouver, BC V6T 1Z3

2. Date of Material Change

November 20, 2007

3. News Release

November 20, 2007 - Vancouver, Canada

4. Summary of Material Change

Cardiome Pharma Corp. today announced initiation of subject dosing in its Phase 1 study of GED-aPC.  The single-blinded, placebo-controlled, dose-ranging study will measure the safety, tolerability, pharmacokinetics and pharmacodynamics of GED-aPC in 24 healthy subjects, with each subject receiving a 15-minute loading dose at the start of a 24-hour continuous intravenous infusion of GED-aPC.  Results from this study are expected in the first half of 2008.

5. Full Description of Material Change

See attached press release

6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not Applicable.

7. Omitted Information

Not Applicable.

8. Executive Officer

Name:      Curtis Sikorsky

Title:            Chief Financial Officer

Phone No.: 604-677-6905

9. Date of Report

November 20, 2007

Per:	“Curtis Sikorsky”
	Curtis Sikorsky, Chief Financial Officer